Navigation Links
New Drug Delivery System to Improve Cancer Treatment
Date:3/16/2011

SYRACUSE, N.Y., March 16, 2011 /PRNewswire/ -- Scientists in Syracuse University's Chemistry Department have created a new drug delivery system expected to advance the effectiveness of cancer-killing drugs. It uses gold nanoparticles with attached DNA that binds to a proven anti-cancer drug, Doxorubicin or DOX.

Preliminary tests indicate this delivery device has the potential to significantly improve the results of cancer chemotherapy. DOX is currently used against cancers of the breast, bone marrow, thyroid, bladder, ovary, small cell lung and several others.

"The possibilities of this new system are really exciting," says SU Professor James C. Dabrowiak. "For example, it would be easy to add to the device molecules that have the ability to target cancer cells. Another possibility is using light excitation to release high concentrations of an anti-tumor drug directly within the tumor."

These and other upgrades could enable clinics to focus chemotherapy more tightly on cancer cells and reduce negative side effects on healthy cells in other parts of the body.

A key element of the new system is that the DNA attached to the gold particles is engineered specifically to bind to the DOX anti-tumor drug. Studies show that the DOX can be transferred by diffusion to a receptor DNA molecule.

The gold nanoparticles have an average diameter of only 15.5 nanometers or a few billionths of a meter. A single nanoparticle presents more than 100 DOX sites and that, when multiplied by millions of the particles, could create a massive and deadly assault on a tumor.

"We believe this work can bring significant gains in the effectiveness of chemotherapy treatments," says Mathew M. Maye, SU Assistant Professor of Chemistry and co-inventor of the delivery system. "We still have work to do but this advance opens a promising new field of investigation that can lead to important new clinical tools."

A key advantage of the new system is that the DOX anti-tumor drug is already accepted by the FDA. Other such drugs may be deployed using this system simply by engineering the DNA to bind to a different drug molecule.

The Syracuse laboratory is continuing investigations to check the toxicity of the system. They will also explore "smart" particles capable of attaching to cancer cells and responding to triggers that will activate drug release. Prior discoveries demonstrate that such nano-delivery systems may be within reach and could help deliver large payloads of anti-tumor drugs where needed.

Graphic: Attacking Cancer with Tiny Drug Carriers

http://www.ereleases.com/pic/Syracuse-gold-nano.jpg

The work of the Syracuse University team was published in a February 2011 issue of ChemComm, a publication of the Royal Society of Chemistry. For more information and access to explanatory graphics, call (315) 443-4601 / 443-2146 or e-mail jcdabrow@syr.edu / mmmaye@syr.eduFor information, contact: Prof. James C. Dabrowiak(315) 443-4601 jcdabrow@syr.edu-or-Prof. Mathew M. Maye(315) 443-2146 mmmaye@syr.eduThis press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Syracuse University Office of Technology Transfer and Industrial Development
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spherics, Inc. Offers Once Daily Extended Release Formulation for Sustained and Stable Pramipexole Delivery
2. Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System
3. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
4. CEL-SCI Takes Delivery of New Manufacturing Facility
5. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
6. MonoSol Rx and Midatech Group Enter Collaboration Agreement to Unite Nanoparticle and Thin Film Drug Delivery Technologies
7. Probiotic Delivery Technology Awarded Third International Patent
8. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
9. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
10. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
11. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... The Global Microfluidic Chips Market by Manufacturers, ... and comprehensive study on the existing state of the global Microfluidic ... Europe and Asia-Pacific , ... and Africa . ... Browse 172 Tables and Figures, 13 Major Company ...
(Date:3/28/2017)... ... March 28, 2017 , ... NetDimensions announced today that ... enhance training plan management for consistent implementation of standards and regulatory requirements across ... Group to help improve and streamline their training and employee development programs, which ...
(Date:3/28/2017)... California (PRWEB) , ... March 28, 2017 , ... ... its flagship product, AllegroGraph , has been named a ‘Champion’ by Bloor Research ... is the highest ranked product in its class, and, thanks to Gruff, it was ...
(Date:3/28/2017)... Ann Arbor, Michigan (PRWEB) , ... March 28, ... ... company was awarded a Phase II Small Business Innovation Research (SBIR) grant from ... will receive approximately $750,000 over two years to develop a suite of BioGel™ ...
Breaking Biology Technology:
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
(Date:3/9/2017)... MELBOURNE , Australia , March ... clinical study data at the prestigious World Lung Imaging ... Dr. Andreas Fouras , was invited to deliver ... and pulmonary medicine. This globally recognised event brings together ... and share the latest developments in lung imaging. ...
(Date:3/7/2017)... 7, 2017   HireVue , the leading provider ... identify the best talent, faster, today announced the additions ... (CSO) and Diana Kucer as Chief Marketing ... executive team poised to drive continued growth in the ... year of record bookings in 2017. "Companies ...
Breaking Biology News(10 mins):